S&P 500
(1.03%) 5 180.74 points
Dow Jones
(0.46%) 38 852 points
Nasdaq
(1.19%) 16 349 points
Oil
(0.32%) $78.73
Gas
(-1.64%) $2.16
Gold
(0.13%) $2 334.30
Silver
(-0.05%) $27.60
Platinum
(0.40%) $968.80
USD/EUR
(0.06%) $0.929
USD/NOK
(0.18%) $10.84
USD/GBP
(0.04%) $0.796
USD/RUB
(0.00%) $91.35

Aktualne aktualizacje dla Oxurion NV [OXUR.BR]

Giełda: EURONEXT Branża: Biotechnology
Ostatnio aktualizowano6 geg. 2024 @ 18:35

0.00% 0.000200

Live Chart Being Loaded With Signals

Commentary (6 geg. 2024 @ 18:35):

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction...

Stats
Dzisiejszy wolumen 129.10M
Średni wolumen 104.90M
Kapitalizacja rynkowa 1.48M
EPS €0 ( 2024-04-05 )
Last Dividend €0 ( N/A )
Next Dividend €0 ( N/A )
P/E 0
ATR14 €0 (0.00%)

Oxurion NV Korelacja

10 Najbardziej pozytywne korelacje
10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Oxurion NV Finanse

Annual 2023
Przychody: €263 000
Zysk brutto: €104 000 (39.54 %)
EPS: €-0.0115
FY 2023
Przychody: €263 000
Zysk brutto: €104 000 (39.54 %)
EPS: €-0.0115
FY 2022
Przychody: €595 000
Zysk brutto: €-271 000 (-45.55 %)
EPS: €-0.370
FY 2021
Przychody: €1.13M
Zysk brutto: €516 000 (45.74 %)
EPS: €-0.928

Financial Reports:

No articles found.

Oxurion NV

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

O Sygnały na żywo

Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.

Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej